Hey Maddi -- no news today on: Today @ 4:00 – 5:30 pm Session IV: Case Studies #1 -- Jakafi - Incyte Corporation (ruxolitinib phosphate)
Case studies are conducted concurrently, and will be repeated on Thursday and Friday. Learners will have the opportunity to attend all three case studies. •Jakafi - Incyte Corporation (ruxolitinib phosphate)
A kinase inhibitor indicated for treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.